Efficacy and tolerability of lopinavir/ritonavir combined with either maraviroc or emtricitabine/tenofovir disoproxil fumarate in antiretroviral-naive HIV-infected patients

Trial Profile

Efficacy and tolerability of lopinavir/ritonavir combined with either maraviroc or emtricitabine/tenofovir disoproxil fumarate in antiretroviral-naive HIV-infected patients

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2011 Interim results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.
    • 16 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top